Amicus Therapeutics, Inc. (NASDAQ:FOLD) saw an uptick in trading volume on Wednesday . 647,346 shares traded hands during trading, a decline of 81% from the previous session’s volume of 3,457,649 shares.The stock last traded at $15.12 and had previously closed at $15.16.
A number of research firms have commented on FOLD. Zacks Investment Research downgraded shares of Amicus Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday. BidaskClub downgraded shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, February 13th. Leerink Swann raised their target price on shares of Amicus Therapeutics from $20.00 to $24.00 and gave the company an “outperform” rating in a research report on Thursday, February 8th. Robert W. Baird set a $20.00 target price on shares of Amicus Therapeutics and gave the company a “buy” rating in a research report on Wednesday, February 7th. Finally, ValuEngine raised shares of Amicus Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $19.06.
The stock has a market capitalization of $2,810.85, a price-to-earnings ratio of -8.29 and a beta of 1.60. The company has a debt-to-equity ratio of 0.47, a quick ratio of 5.53 and a current ratio of 5.60.
Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.11). Amicus Therapeutics had a negative net margin of 769.03% and a negative return on equity of 71.06%. The firm had revenue of $14.73 million during the quarter, compared to the consensus estimate of $14.50 million. sell-side analysts expect that Amicus Therapeutics, Inc. will post -1.26 earnings per share for the current fiscal year.
In other news, major shareholder Perceptive Advisors Llc purchased 335,827 shares of the stock in a transaction dated Monday, March 5th. The shares were acquired at an average cost of $13.56 per share, for a total transaction of $4,553,814.12. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO William D. Baird III sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $14.72, for a total transaction of $147,200.00. Following the completion of the sale, the chief financial officer now owns 105,121 shares in the company, valued at $1,547,381.12. The disclosure for this sale can be found here. Insiders sold a total of 207,870 shares of company stock worth $3,066,112 over the last 90 days. Company insiders own 3.40% of the company’s stock.
Large investors have recently added to or reduced their stakes in the company. Sage Capital Advisors llc bought a new stake in shares of Amicus Therapeutics in the 3rd quarter valued at about $154,000. Engineers Gate Manager LP acquired a new stake in Amicus Therapeutics in the 3rd quarter worth approximately $155,000. Neuberger Berman Group LLC acquired a new stake in Amicus Therapeutics in the 3rd quarter worth approximately $196,000. Great West Life Assurance Co. Can boosted its stake in Amicus Therapeutics by 40.2% in the 3rd quarter. Great West Life Assurance Co. Can now owns 14,445 shares of the biopharmaceutical company’s stock worth $212,000 after purchasing an additional 4,145 shares in the last quarter. Finally, Sterling Capital Management LLC acquired a new stake in Amicus Therapeutics in the 3rd quarter worth approximately $218,000.
ILLEGAL ACTIVITY WARNING: This piece of content was first published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.thelincolnianonline.com/2018/03/14/amicus-therapeutics-fold-sees-large-volume-increase.html.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.